MedTrace Logo

Nexium Dyspepsia/AST

NCT00251914 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2011-01-24

No results posted yet for this study

Summary

The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.

Conditions

  • Gastrointestinal Disease
  • Signs and Symptoms, Digestive
  • Dyspepsia

Interventions

DRUG

Esomeprazole

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Nexium Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • Argentina
  • Belgium
  • Brazil
  • Canada
  • Denmark
  • France
  • Germany
  • Greece
  • Iceland
  • Italy
  • Norway
  • Romania
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00251914 on ClinicalTrials.gov